LianBio Secures $310 Million Crossover Financing to Advance Innovative Therapies for Cardiovascular, Renal, and Oncology Diseases in China and Asia

Shanghai and Princeton, New Jersey – October 29, 2020 – LianBio, a China-based company focused on bringing transformative medicines to patients in China and key Asian markets, today announced that it has successfully raised an oversubscribed $310 million cross-round financing, following its founding and initial funding from Perceptive Advisors.

This round of financing was co-led by renowned U.S. biopharmaceutical investment firms RA Capital and Venrock Healthcare Capital Partners, together with China’s private equity management firm SDIC Investment Management. Other biopharmaceutical investors in this round included funds under BlackRock Asset Management, Casdin Capital, Farallon, Logos Capital, Perceptive Advisors, Pfizer, Sphera Global Health Care, funds under T. Rowe Price Associates, Inc., Tybourne Capital Management, Vida Ventures, Viking Global Investors, and Wellington Management.

“We are delighted to partner with these world-class investors who share our vision of accelerating the availability of innovative medicines with disruptive potential for patients in China and other major Asian markets. Building on the momentum from LianBio’s recent establishment and subsequent successful development, this financing round provides further support for the company to continue addressing the significant unmet clinical needs in the aforementioned regions and contributing to the advancement of China’s life sciences sector,” said Konstantin Poukalov, Managing Director at Perceptive Advisors and Executive Chairman of LianBio. “We take pride in the exceptional execution capabilities of our management team, who are accelerating the realization of our vision and demonstrating that teamwork, strong passion for clinical R&D, and commitment can facilitate the rapid launch of the world’s most innovative drugs in the Chinese pharmaceutical market.”

This round of financing demonstrates that the company’s global innovation expansion platform has gained recognition from top-tier global investors. LianBio is confident in continuing to advance its business model in China and other major Asian markets. SDIC Investment Management will also fully leverage its industrial ecosystem resources in China’s pharmaceutical and healthcare sectors to support LianBio’s rapid and healthy development in the Chinese market.

Jefferies LLC served as the exclusive financial advisor for this round of financing.

About LianBio

LianBio’s mission is to deliver high-quality, disruptive therapeutics and scientific treatments to patients in China and other key Asian markets through efficient product development, enabled by strategic collaborations with leading global biopharmaceutical companies. By partnering with world-class collaborators across diverse therapeutic areas and geographies, LianBio has built a disease-focused pipeline that leverages translational mechanisms and precision therapies to improve patient outcomes. For more information, please visit lianbio.com.

About SDIC Merchants

SDIC China Merchants is a professional private equity management firm, with its team managing cumulative assets exceeding RMB 100 billion. Its investors include financial institutions, the National Social Security Fund, as well as state-owned and private capital. The management team has long focused on investments in the advanced manufacturing industry, emphasizing the value of technological innovation and outstanding entrepreneurs and teams. It prioritizes investments in fields such as intelligent manufacturing, smart and new energy vehicles, life sciences, and information and communications technology (ICT), committing to promote the green, digital, and service-oriented development of the manufacturing sector.

Investor Contact:

ThomasHoffmann

SoleburyTrout

+1646-378-2931

thoffmann@soleburytrout.com

Media Contact:

VincentLian

EasyPR

+8618616687388

Lv@easy-pr.hk

HannahGendel

SoleburyTrout

+1646-378-2943

hgendel@soleburytrout.com

Responsible Editor: Penicillin

This article is reposted from Yaozhi.com. The copyright of all images and text belongs to the original authors. The purpose of this repost is to convey more information, which does not represent the views of this platform. If there are any issues related to the content, copyright, or other matters, please leave a message on our website, and we will remove the content promptly.